TauRx Pharmaceuticals
TauRx Pharmaceuticals is a Singapore-headquartered, privately held life sciences company developing HMTM, an oral tau aggregation inhibitor for Alzheimer's disease and frontotemporal dementia, currently awaiting MHRA approval. It serves MCI and Alzheimer's patients via pharmaceutical sales and operates a diagnostic joint venture.
- Company typePrivate
- Founded2002
- HeadquartersSingapore, Singapore
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What TauRx Pharmaceuticals does
TauRx Pharmaceuticals is a privately held life sciences company founded in 2002 in Singapore, developing disease-modifying treatments and diagnostic tools for neurodegenerative diseases, with a primary focus on Alzheimer's disease and frontotemporal dementia. The company's core technology is a proprietary Tau Aggregation Inhibitor (TAI) platform based on hydromethylthionine mesylate (HMTM), an oral small-molecule compound discovered through research initiated by co-founder Prof Claude Wischik in 1988 and 1996. HMTM targets tau tangle pathology in the brain via a mechanism distinct from anti-amyloid approaches, and is administered as a film-coated tablet designed for early intervention in mild cognitive impairment (MCI) and mild-to-moderate Alzheimer's disease.
The company has completed Phase III clinical trials (LUCIDITY) involving approximately 3,000 patients across North America and Europe, demonstrating pharmacological activity on clinical decline and brain atrophy. In 2022, TauRx submitted HMTM to the UK Medicines and Healthcare products Regulatory Agency (MHRA) for approval and received an Innovation Passport acknowledging innovative potential; a confirmatory study was published in the Journal of Prevention of Alzheimer's Disease in 2024. The company is incorporated in Scotland (TauRx Therapeutics Management Limited, Registered Number SC531195) and operates from headquarters in Singapore with a UK operational base in Aberdeen. It has a leadership team led by Prof Claude Wischik (Co-Founder, Chairman and CEO), Dr Glenn Corr (COO/CBO), Prof Bjoern Schelter (Chief Analytics Officer), Prof John Storey (CTO), and Dr Richard Stefanacci (CMO).
TauRx is pre-commercial and pre-revenue, with no products currently generating sales. The planned business model upon regulatory approval is prescription pharmaceutical sales through healthcare systems, hospitals, and pharmacies, supported by the company's joint venture GT Diagnostics (with Genting Berhad) which develops digital diagnostic tools for early dementia detection and progression monitoring. The company has been funded through multiple private rounds totaling over $377 million since 2012, with Dundee Corporation holding approximately 1,007,008 shares at US$125/share as of 2024.
TauRx Pharmaceuticals firmographics
Firmographics- Name
- TauRx Pharmaceuticals
- Legal name
- TauRx Therapeutics Management Limited
- Website
- http://taurx.com
- Company type
- Private
- Founded year
- 2002
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- TauRx Pharmaceuticals is a Singapore-headquartered, privately held life sciences company developing HMTM, an oral tau aggregation inhibitor for Alzheimer's disease and frontotemporal dementia, currently awaiting MHRA approval. It serves MCI and Alzheimer's patients via pharmaceutical sales and operates a diagnostic joint venture.
- Ownership category
- akta.pro rank
TauRx Pharmaceuticals industry classification
Industry- Product category
- Alzheimer's Disease Therapeutics
- NAICS
- Medicinal and Botanical Manufacturing (325411)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)
- akta.pro secondary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
Keywords
Where TauRx Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Singapore
- HQ country
- Singapore
- HQ region
- Asia
Offices2 records
Markets served
TauRx Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- HMTM Pharmaceutical Sales: Pre-commercial stage. HMTM has been submitted for regulatory approval to MHRA as a tablet to treat MCI and mild to moderate Alzheimer's disease. Once approved, the company will generate revenue through prescription pharmaceutical sales. The company states HMTM has a strong safety profile not requiring expensive tests or scans for routine monitoring, potentially offering cost advantages.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels6 records
TauRx Pharmaceuticals product offering
Product offeringCore offering
TauRx Pharmaceuticals is developing hydromethylthionine mesylate (HMTM), an oral, film-coated tablet that acts as a Tau Aggregation Inhibitor (TAI) targeting tau pathology in the brain to modify disease progression in mild cognitive impairment (MCI) and mild-to-moderate Alzheimer's disease. The compound has completed Phase III clinical trials (LUCIDITY) and has been submitted to the UK's MHRA for regulatory approval as the company's first commercial product. Through its GT Diagnostics joint venture, the company also develops digital tools for early dementia diagnosis and progression monitoring.
Product overview
TauRx Pharmaceuticals is a life sciences company focused on developing treatments for Alzheimer's disease and other neurodegenerative diseases caused by protein aggregation. The company's core product is HMTM (hydromethylthionine mesylate), an oral tau aggregation inhibitor tablet that has completed Phase III clinical trials (LUCIDITY) and was submitted for regulatory approval to the UK's MHRA in 2024. Complementary to its treatment pipeline, TauRx operates through a joint venture GT Diagnostics focused on digital diagnostic tools for dementia. The company was founded in 2002 in Singapore with roots in both Singapore and the United Kingdom.
Differentiator
Problem solved
Functional benefit
Brands
- HMTM (Hydromethylthionine Mesylate): Oral tau aggregation inhibitor tablet for treatment of mild cognitive impairment and mild to moderate Alzheimer's disease
- GT Diagnostics
Products and services
- HMTM (Hydromethylthionine Mesylate) Oral, film-coated tablet formulated as a Tau Aggregation Inhibitor (TAI) for early intervention in Alzheimer's disease to modify the underlying disease process and slow progression. Designed to dissolve tau tangles in the brain through a mechanism distinct from anti-amyloid therapies, with a strong safety profile requiring minimal routine monitoring (no expensive scans or tests). Targeted at patients with mild cognitive impairment and mild-to-moderate Alzheimer's disease, prescribed by neurologists, geriatricians, and primary care physicians.
Quantifiable outcome
- Phase III trials demonstrated pharmacological activity on clinical decline and brain atrophy in Alzheimer's disease and frontotemporal dementia
- +2 more outcomes
Companies that use TauRx Pharmaceuticals
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles3 records
TauRx Pharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
TauRx Pharmaceuticals partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- GT Diagnostics (Joint Venture with Genting Berhad)coreTauRx collaborates with Genting Berhad to create the joint venture GT Diagnostics, which aims to change the diagnostic landscape of dementia by developing tools for early diagnosis and monitoring progression. Focus on using digital tools to address bottlenecks in the diagnostic pathway, aiding clinicians to streamline dementia diagnosis. This is complementary to TauRx's research expertise focused on developing treatments.
Scale indicators4 records
Recent moves3 records
Expansion highlights6 records
TauRx Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- Cassava Sciences: Late-stage clinical biopharma focused on a disease-modifying oral therapy (simufilam) for Alzheimer's disease, directly comparable in target indication, modality (oral small molecule), and pre-commercial regulatory stage.
- AC Immune: Clinical-stage biopharma developing therapeutics and diagnostics targeting tau and other misfolded proteins in Alzheimer's and neurodegeneration, comparable in tau-pathology focus and integrated diagnostic-therapeutic strategy.
- Anavex Life Sciences: Clinical-stage biopharma developing small-molecule therapies for Alzheimer's disease and other neurodegenerative conditions, with a similar late-stage CNS profile and similar go-to-market through regulatory submissions in Alzheimer's.
- Axon Neuroscience: Tau-pathology-focused clinical-stage biopharma developing vaccines and therapeutics for Alzheimer's and frontotemporal dementia, directly comparable in tau-targeting approach and neurodegenerative focus.
- Cognition Therapeutics: Clinical-stage CNS biopharma developing small-molecule therapies for Alzheimer's disease, sharing a similar late-stage private/early-public profile and oral small-molecule CNS modality.
Broad incumbents
- Eli Lilly: Large pharma that developed and launched Kisunla (donanemab) for early symptomatic Alzheimer's disease, a direct therapeutic competitor to HMTM in the same target population.
- Eisai: Large Japanese pharmaceutical company co-developing and commercializing Leqembi (lecanemab), an approved anti-amyloid Alzheimer's therapy, making it the most direct large-pharma competitor for HMTM in the same disease.
- Biogen: Global neurology-focused biopharma co-marketing Leqembi and previously launching Aduhelm, representing the established Alzheimer's commercial competitor with deep payer and prescriber relationships.
Emerging players
- Denali Therapeutics: Clinical-stage biopharma developing therapeutics for neurodegenerative diseases with an emphasis on biological targets and CNS delivery, comparable in neurodegeneration focus and platform-style pipeline approach.
- BioVie: Clinical-stage biopharma developing therapies for Alzheimer's disease and other neurological conditions, comparable in late-stage CNS pipeline and pre-commercial regulatory positioning.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
TauRx Pharmaceuticals social profiles
Digital presenceTauRx Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
TauRx Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles5 records
TauRx Pharmaceuticals subsidiaries and ownership
Company hierarchySubsidiaries1 record
TauRx Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds6 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
TauRx Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about TauRx Pharmaceuticals
What does TauRx Pharmaceuticals do?
TauRx Pharmaceuticals is developing hydromethylthionine mesylate (HMTM), an oral, film-coated tablet that acts as a Tau Aggregation Inhibitor (TAI) targeting tau pathology in the brain to modify disease progression in mild cognitive impairment (MCI) and mild-to-moderate Alzheimer's disease. The compound has completed Phase III clinical trials (LUCIDITY) and has been submitted to the UK's MHRA for regulatory approval as the company's first commercial product. Through its GT Diagnostics joint venture, the company also develops digital tools for early dementia diagnosis and progression monitoring.
Is TauRx Pharmaceuticals a public or private company?
TauRx Pharmaceuticals is a private company. It is classified as venture growth investor backed and is currently operating.
When was TauRx Pharmaceuticals founded?
TauRx Pharmaceuticals was founded in 2002. It employs 501 to 1,000 people.
Where is TauRx Pharmaceuticals based?
TauRx Pharmaceuticals is headquartered in Singapore, Singapore, in the Asia region.
How does TauRx Pharmaceuticals make money?
One revenue line is on record: HMTM Pharmaceutical Sales.
Who are TauRx Pharmaceuticals's main competitors?
Direct peers on record are Cassava Sciences, AC Immune, Anavex Life Sciences, Axon Neuroscience and Cognition Therapeutics. Broad incumbents are Eli Lilly, Eisai and Biogen. Emerging players are Denali Therapeutics and BioVie.
Does TauRx Pharmaceuticals have an API?
No public API is recorded for TauRx Pharmaceuticals.
What industry is TauRx Pharmaceuticals in?
TauRx Pharmaceuticals's product category is Alzheimer's Disease Therapeutics. Its primary akta.pro industry code is HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 325411 and its SIC code is 2834.